Clinical trial · Interventional
Study of Pemetrexed Versus Pemetrexed Plus Erlotinib as Treatment of Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
A Phase 2 Study of Pemetrexed Versus Pemetrexed Plus Erlotinib in Second-Line Treatment in Patients With Nonsquamous NSCLC
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a multicenter, randomized, Phase 2, open label, parallel trial to evaluate an effect of pemetrexed alone on nonsquamous non-small cell lung cancer (NSCLC) in a second-line setting (such as progression-free survival \[PFS\], disease control rate, best response rate, time to treatment failure \[TTTF\], overall survival \[OS\] and 1-year survival rates) compared to pemetrexed plus erlotinib combination.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Histological or Cytological Diagnosis of Locally Advanced or Metastatic NSCLC of Nonsquamous Histology and Not Amenable to Curative Therapy. | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erlotinib | Drug | Erlotinib | ALIAS |
| Pemetrexed | Drug | Pemetrexed | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- Pemetrexed (Nonsquamous)
- description
- Group of participants with non-small cell lung cancer (NSCLC) of nonsquamous histology who were assigned to Pemetrexed arm
- interventionNames
- Drug: Pemetrexed
- type
- EXPERIMENTAL
- label
- Pemetrexed + Erlotinib (Nonsquamous)
- description
- Group of participants with NSCLC of nonsquamous histology who were assigned to Pemetrexed + Erlotinib arm
- interventionNames
- Drug: Erlotinib
- Drug: Pemetrexed
- type
- EXPERIMENTAL
- label
- Pemetrexed (Squamous)
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histological or cytological diagnosis of locally advanced or metastatic NSCLC that is of nonsquamous histology and not amenable to curative therapy. * Failure of previous treatment with one prior platinum-based chemotherapy regimen. * Good performance status. * Adequate bone marrow reserve, renal and hepatic functions. Exclusion Criteria: * Serious concomitant systemic disease. * Inability to take oral medication. * Inability or unwillingness to take vitamin supplementation and corticosteroids. * Pregnancy / Breast-feeding. * Treatment with certain medicines that prevent blood from clotting.
References
Publications (0)
Data not yet available